With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

Sensorion has two therapeutic solutions being evaluated in clinical trials (SENS-111 to treat acute unilateral vestibulopathy and SENS-401 to treat sudden sensorineural hearing loss).

Our R&D teams are conducting studies to select drugs for prevention of ototoxicity.

 

 

pipeline2017

Latest news

  • 08 Jun 2017

    Sensorion Announces Results from 2017 Annual General Meeting: Appointments of Dominique Costantini and Nawal Ouzren to Company’s Board of Directors Approved Read

  • 08 Jun 2017

    Sensorion takes a key step towards phase 2 with SENS-401 thanks to the positive results obtained in the phase 1 clinical trial Read

Patient center

Corporate presentation